Despite its efficacy in restoring healthy commensal microbial populations and reducing colitis-associated inflammation, experimental data using colitis susceptible IL-10−/− mice have shown that VSL#3 may increase tumor multiplicity, penetrance, histopathological dysplasia, and adenocarcinoma invasion under azoxymethane-treatment [258]. Here, IL10 is linked to colitis.